real-time news and commentary for investors
Wednesday, Dec 19
2012, 4:40 PM
GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming...
GlaxoSmithKline (GSK) reaches a $150M preliminary settlement with U.S. drug wholesalers claiming the company improperly delayed the market entry of competitive generic alternatives to its nasal spray Flonase. The settlement was reached with AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK), among others, who maintained that GSK had abused the citizen's petition process to monopolize the market and overcharge for the spray by restricting access to less expensive generic versions.